Overview

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

Status:
Completed
Trial end date:
2017-12-15
Target enrollment:
Participant gender:
Summary
The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).
Phase:
Phase 2
Details
Lead Sponsor:
Sherif S. Farag
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Sitagliptin Phosphate